[HTML][HTML] Engineering interferons and interleukins for cancer immunotherapy
Cytokines are a class of potent immunoregulatory proteins that are secreted in response to
various stimuli and act locally to regulate many aspects of human physiology and disease …
various stimuli and act locally to regulate many aspects of human physiology and disease …
Spatiotemporally programming cytokine immunotherapies through protein engineering
L Santollani, KD Wittrup - Immunological Reviews, 2023 - Wiley Online Library
Cytokines have long been considered promising cancer immunotherapy agents due to their
endogenous role in activating and proliferating lymphocytes. However, since the initial FDA …
endogenous role in activating and proliferating lymphocytes. However, since the initial FDA …
[HTML][HTML] TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent …
DB Rosen, AM Kvarnhammar, B Laufer… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Recombinant interleukin-2 (IL-2, aldesleukin) is an approved cancer
immunotherapy but causes severe toxicities including cytokine storm and vascular leak …
immunotherapy but causes severe toxicities including cytokine storm and vascular leak …
IL-2 based cancer immunotherapies: an evolving paradigm
Discovered over 4 decades ago in the supernatants of activated T cells, interleukin-2 (IL-2)
is a potent pleiotropic cytokine involved in the regulation of immune responses. It is required …
is a potent pleiotropic cytokine involved in the regulation of immune responses. It is required …
NL-201 upregulates MHC-I expression and intratumoral T-cell receptor diversity, and demonstrates robust antitumor activity as monotherapy and in combination with …
C Mortales, B Dutzar, J Chen, A Chen… - Cancer Immunology …, 2023 - aacrjournals.org
Cytokine engineering has shown promise as a means to create novel immunomodulatory
agents or to improve upon the therapeutic potential of natural cytokines. NL-201, a de novo …
agents or to improve upon the therapeutic potential of natural cytokines. NL-201, a de novo …
563 ICT01, an anti-BTN3A mAb, and NL-201, an alpha-independent IL-2/IL-15 agonist, combine to elicit a potent anti-tumor response by synergistically stimulating …
A De Gassart, P Brune, M Mairesse, S Agaugué… - 2021 - jitc.bmj.com
Background γ9δ2 T-cells are attractive mediators of cancer immunotherapy due to their
strong cytolytic and pro-inflammatory activities and the positive correlation between tumor …
strong cytolytic and pro-inflammatory activities and the positive correlation between tumor …
NL-201, a de novo agonist of IL-2 and IL-15 receptors, demonstrates antitumor activity in preclinical B cell lymphoma models
NL-201 is a computationally-designed IL-2/IL-15 cytokine mimetic under investigation in a
phase 1 clinical trial for patients with solid tumors. This de novo protein signals through the …
phase 1 clinical trial for patients with solid tumors. This de novo protein signals through the …